Skip to main content
    T

    TriSalus Life Sciences Inc. (TLSI)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $2.27
    -0.16 (-6.58%)

    Market Cap: $149.93M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    TriSalus Life Sciences Inc. (TLSI) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect TriSalus Life Sciences (TLSI) to earn -$0.44 per share in the fiscal year ending Dec 31, 2026, on revenue of $46.76M. Of 5 analysts, 5 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. For the fiscal year ending Dec 31, 2027, the EPS consensus is -$0.35.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 5 ratings average 1.80, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.

    RatingAnalystsShare
    Strong Buy120.0%
    Buy480.0%
    Hold00.0%
    Sell00.0%
    Strong Sell00.0%
    Consensus
    Buy
    Total analysts
    5

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus shows a smaller loss and revenue estimates rise 28.6%.

    Fiscal year ending Dec 31, 2026
    -$0.44
    EPS consensus, revenue $46.76M
    Fiscal year ending Dec 31, 2027
    -$0.35
    EPS consensus, revenue $60.11M

    EPS range

    Revenue range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$0.44-$0.45 to -$0.423$46.76M$46.00M to $47.30M3
    Dec 31, 2027-$0.35-$0.55 to $0.024$60.11M$52.70M to $72.16M4

    Quarterly Estimates

    The EPS consensus falls from -$0.06 for the quarter ending Dec 31, 2026 to -$0.11 for the quarter ending Mar 31, 2027.

    EPS range

    Revenue range

    Quarter endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$0.06-$0.11 to -$0.047$13.81M$12.64M to $14.80M7
    Mar 31, 2027-$0.11-$0.15 to -$0.093$14.49M$10.10M to $17.04M4

    Estimate Revisions

    Across the 2 periods below, the last 30 days brought 1 upward and 0 downward EPS revisions.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Dec 31, 202600
    Fiscal year ending Dec 31, 202710

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$0.33.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026-$0.44-$0.33-$0.33-$0.33-$0.33N/A
    Fiscal year ending Dec 31, 2027-$0.35-$0.26-$0.26-$0.26-$0.26N/A
    Quarter ending Mar 31, 2027-$0.11-$0.10-$0.10-$0.11-$0.11N/A

    Frequently Asked Questions About TLSI

    What is the TLSI stock forecast?

    Consensus analyst estimates put TriSalus Life Sciences's EPS at -$0.44 for the fiscal year ending Dec 31, 2026, on revenue of $46.76M. The consensus rating from 5 analysts is Buy.

    How do analysts rate TLSI stock?

    Of 5 analysts covering TriSalus Life Sciences, 1 rates it Strong Buy, 4 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.

    What EPS do analysts expect from TLSI next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$0.44, with estimates from -$0.45 to -$0.42 from 3 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.35, with estimates from -$0.55 to $0.02 from 4 analysts.

    What revenue do analysts expect from TriSalus Life Sciences next year?

    For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $46.76M, with estimates from $46.00M to $47.30M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $60.11M, with estimates from $52.70M to $72.16M.

    How many analysts cover TLSI?

    5 analysts rate TriSalus Life Sciences stock, and 3 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.